Voraxaze™ is an investigational new
drug that is available in Europe and
elsewhere outside the US on a named
patient basis and in the US under a
Treatment Protocol for patients
receiving high dose methotrexate
(≥1g/m2) who are experiencing or at
risk of, methotrexate toxicity. High
dose methotrexate is used to treat
or prevent the recurrence of certain
types of cancer. Patients are
considered at risk of methotrexate
toxicity if they have impaired renal
function, which can lead to a delay
in methotrexate elimination, or have
evidence of delayed elimination
based on methotrexate levels.
DigiFab™, Digoxin Immune
Fabs (Ovine)
For the treatment of patients with
life-threatening, or potentially
life-threatening, digoxin toxicity.
